Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Gross Margin (2019 - 2025)

Historic Gross Margin for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to 83.14%.

  • Bioadaptives' Gross Margin changed N/A to 83.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.59%, marking a year-over-year increase of 287300.0%. This contributed to the annual value of 31.81% for FY2024, which is 60700.0% down from last year.
  • According to the latest figures from Q3 2025, Bioadaptives' Gross Margin is 83.14%.
  • Bioadaptives' Gross Margin's 5-year high stood at 83.14% during Q3 2025, with a 5-year trough of 25.85% in Q4 2022.
  • Its 5-year average for Gross Margin is 48.03%, with a median of 52.53% in 2021.
  • In the last 5 years, Bioadaptives' Gross Margin skyrocketed by 510700bps in 2021 and then crashed by -305300bps in 2025.
  • Bioadaptives' Gross Margin (Quarter) stood at 29.65% in 2021, then fell by -13bps to 25.85% in 2022, then surged by 45bps to 37.48% in 2023, then surged by 70bps to 63.56% in 2024, then surged by 31bps to 83.14% in 2025.
  • Its last three reported values are 83.14% in Q3 2025, 33.02% for Q2 2025, and 63.56% during Q2 2024.